Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19.
Vaccines
Virology
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
06
2020
accepted:
14
07
2020
entrez:
15
8
2020
pubmed:
15
8
2020
medline:
15
8
2020
Statut:
epublish
Résumé
Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres.
Identifiants
pubmed: 32793398
doi: 10.1038/s41541-020-00221-3
pii: 221
pmc: PMC7385486
doi:
Types de publication
Journal Article
Langues
eng
Pagination
69Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/I/00007031
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/I/00007039
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/I/00007038
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/I/00007037
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/I/00007034
Pays : United Kingdom
Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsS.C.G. and T.L. are named on a patent application covering ChAdOx1 nCoV-19. The remaining authors declare no competing interests. The funders played no role in the conceptualisation, design, data collection, analysis, decision to publish, or preparation of the manuscript.
Références
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
J Mol Med (Berl). 2018 Apr;96(3-4):249-263
pubmed: 29302700
Emerg Microbes Infect. 2020 Dec;9(1):761-770
pubmed: 32228226
PLoS Negl Trop Dis. 2019 Jun 6;13(6):e0007462
pubmed: 31170144
Vaccines (Basel). 2020 Mar 02;8(1):
pubmed: 32131403
J Immunol. 2018 Jun 15;200(12):4068-4077
pubmed: 29703861
Front Vet Sci. 2019 Feb 04;6:16
pubmed: 30778392
Vaccine. 2011 Aug 11;29(35):5892-903
pubmed: 21723900
Lancet Infect Dis. 2020 Jul;20(7):816-826
pubmed: 32325038
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Front Immunol. 2019 Nov 08;10:2625
pubmed: 31787986
Discov Med. 2014 Dec;18(101):313-22
pubmed: 25549702
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
NPJ Vaccines. 2017 Oct 16;2:28
pubmed: 29263883
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
ILAR J. 2015;56(1):53-62
pubmed: 25991698
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
Emerg Infect Dis. 2020 Oct;26(10):2484-2487
pubmed: 32579877
Cell Mol Immunol. 2020 May;17(5):541-543
pubmed: 32203186
Trends Microbiol. 2012 Jan;20(1):50-7
pubmed: 22153753
J Immunol. 2016 Jun 15;196(12):5014-23
pubmed: 27183611
Sci Adv. 2020 Jun 10;6(24):eaba8399
pubmed: 32577525
Vaccine. 2019 Sep 3;37(37):5567-5577
pubmed: 31399277